key: cord-0852704-lc599zl4
authors: Halani, Sheliza; Andany, Nisha; Izenberg, Aaron; Auguste, Bourne
title: Acute confusion in a 55-year-old man with end-stage renal disease
date: 2022-03-21
journal: CMAJ
DOI: 10.1503/cmaj.211357
sha: 4367688227ee23055d448a40a2337fac7ae5f54a
doc_id: 852704
cord_uid: lc599zl4

nan

a. Uremic encephalopathy b. Drug-induced aseptic meningitis c. Valacyclovir neurotoxicity d. Viral encephalitis e. Hypertensive encephalopathy Our primary consideration was valacyclovir neurotoxicity (c). This entity has been well described in patients with underlying end-stage renal disease, particularly when dose adjustment is not performed. In patients receiving peritoneal dialysis, the recommended dosage of valacyclovir is 500 mg every 24 hours. 1, 2 The timing of our patient's symptoms aligned with the recent initi ation of valacyclovir at 6 times the recommended dose. 3 Our second consideration was viral encephalitis (d), given the combin ation of rash and altered mental status. The absence of fever and the characteristics of the rash, however, argued against this diagnosis. 1 Uremic encephalopathy (a) is a plausible explanation for cognitive changes in any patient with chronic renal disease, but our patient's urea level was similar to his baseline, and he had been on a stable regimen of continuous cycling peritoneal dialysis for 7 months, making this unlikely. 3 We also considered drug-induced meningitis and meningitis due to infection were less likely, given the lack of meningeal signs (i.e., nuchal rigidity), fever or symptoms (i.e., headache), despite the presence of confusion and agitation. 3 Hypertension is common among patients receiving dialysis, and patients who have been on dialysis for some time may be more resistant to antihypertensive treatment than patients starting dialysis. Our patient's CT scan did not show hemorrhagic infarct nor edematous areas to suggest posterior reversible leukoencephalopathy syndrome. 4

What is the most appropriate next step? a. Start empiric intravenous (IV) acyclovir b. Order magnetic resonance imaging (MRI) of the brain c. Perform a lumbar puncture d. Switch to hemodialysis e. Order electroencephalography (EEG)

The most appropriate next step in management is lumbar puncture (c), given the importance of viral encephalitis in our differential diagnosis. Cerebrospinal fluid (CSF) analysis showed lymphocytic pleocytosis with normal glucose and mildly elevated protein ( Table 2 ). Microbiologic studies for bacterial and viral encephalitis, HIV, Lyme disease and cryptococcus were negative ( Table 2 ). In addition to performing a lumbar puncture, we discontinued valacyclovir and commenced acyclovir empirically (5 mg/kg IV every 24 hours [425 mg every 24 hours], adjusted for end-stage renal disease) for possible herpes encephalitis. Delayed treatment of this condition is associated with increased morbidity and mortality, and the risks of withholding treatment outweigh the risks of administering acyclovir if appropriately renally dosed. 5 Of note, acyclovir has a smaller molecular weight than valacyclovir and is cleared both by glomerular filtration and tubular secretion, limiting the overall risk of toxic accumulation. 6 The nephrology team intensified his continuous ambulatory peritoneal dialysis regimen with 6 daily exchanges of hypertonic solution (4.25%), from 4 daily exchanges with 2.5% solution.

We ordered a brain MRI to identify features of encephalitis, such as temporal lobe edema in herpes simplex virus encephalitis ( Figure 2) . The scan showed a subtle signal in the left insular and mesial temporal regions on T 2 fluid-attenuated inversion recovery images. We also performed an EEG to assess for focal or lateralizing abnormalities, which are more frequently seen in herpes simplex virus encephalitis, or seizures. 1 The EEG showed diffuse slowing only. Blood cultures were negative, and although the patient did not have residual urine output to allow for urine culture, peri toneal dialysis fluid was negative for microbiological culture. A midturbinate swab for SARS-CoV-2 infection was negative. Once polymerase chain reaction (PCR) testing of the patient's CSF returned negative for herpes simplex virus and varicella zoster virus, we discontinued acyclovir, as PCR-based testing is highly sensitive for central nervous system infection secondary to these viruses. 7 The patient's clinical status improved beginning on hospital day 4, which was the day after intensification of peritoneal dialysis. He continued to improve, and we discharged him 10 days after presentation. Although he improved somewhat when acyclovir was reduced to renal dosing, a dramatic improvement in symptoms occurred with intensification of peritoneal dialysis. This, paired with lack of fever and negative microbiologic testing, suggested a most likely diagnosis of valacyclovir neurotoxicity with atypical radiographic and CSF findings. The Naranjo scale assessment of probability of adverse drug reaction (ADR) related to valacyclovir revealed a score of 5, which represents probable ADR. 8 At follow-up, 3 weeks postdischarge, our patient returned to baseline function and was able to continue peritoneal dialysis independently at home. The rash had completely resolved when he was reassessed after discharge in the outpatient clinic.

Valacyclovir is a prodrug of the antiviral agent acyclovir. It is converted to acyclovir and L-valine by first-pass metabolism, and about 60%-90% of acyclovir is renally excreted via glomerular filtration and tubular secretion. 6, 9 Acyclovir has a molecular weight of 225 Da, protein binding of 9%-33%, and a volume of distribu-tion of 0.6 L/kg with high water solubility, which are characteristics that allow for clearance via hemodialysis. 6 Both acyclovir and valacyclovir are generally well tolerated, but valacyclovir is often preferred for the treatment of herpes simplex and zoster infections because it requires less frequent dosing. 9, 10 The most common adverse drug reaction associated with acyclovir is renal impairment, caused by precipitation of acyclovir crystals in renal tubules, resulting in impaired clearance and increased accumulation of the agent in the blood. 3, 9 Neurotoxicity is an uncommon adverse event associated with acyclovir and valacyclovir use, and literature suggests that neurologic and psychiatric manifestations may be secondary to the metabolite 9-carboxymethoxymethylguanine (CMMG). 9 Predominant risk factors are increased age, renal impairment and malignancy. 1 In a review of 35 published cases of acyclovir neurotoxicity, doses of acyclovir ranged between 600 mg/d and 4000 mg/d. 1 Neurotoxicity can occur even when dosing is appropriately adjusted for renal function. 6 Valacyclovir has been associated with both nephrotoxicity and neurotoxicity. 6 When creatinine clearance is less than 10 mL/min, recommended dosing of valacyclovir is 500 mg every 24 hours. 11

Symptom onset with acyclovir and valacyclovir neurotoxicity is acute, typically within 24-72 hours of treatment initiation, but 1 case report described onset 120 days after initiation. 1, 3 There is a wide spectrum of neuropsychosis manifestations, including hallucinations, confusion and delirium. The exact mechanism is unclear but is suspected to be a result of accumulation of CMMG metabolite. 9 Fever and headache are typically absent, allowing for possible distinction between antiviral toxicity and infectious encephalitis. 1 Descriptions of CSF abnormalities with acyclovir and valacyclovir neurotoxicity can be difficult to interpret. In a review of 35 cases of acyclovir neurotoxicity, CSF was abnormal in 8 of 15 patients who underwent lumbar puncture. 1 However, the authors noted plausible alternative explanations for the abnormalities, including concomitant central nervous system tumours, previous meningoencephalitis and receipt of intrathecal medications. 1 In another review of published cases of acyclovir neurotoxicity, only 1 of 18 patients who underwent a lumbar puncture had pleocytosis (30 leukocytes/µL) and for this reason, the authors argued that presence of inflammatory cells may help distinguish acyclovir toxicity from infectious encephalitis. 12 Additional cases of acyclovir neurotoxicity with abnormal CSF findings -namely, pleocytosis (37 leukocytes/µL with 100% monocytes) and elevated protein (640 mg/L) -have been reported. 11 Brain MRI findings in acyclovir neurotoxicity can vary from normal to subcortical bi-hemispheric lesions on T 1 -weighted MRI, the latter described in a patient with acyclovir neuro toxicity and seizures after blood stem cell transplantation. 13

Acyclovir and valacyclovir neurotoxicity improve after drug discontinuation or elimination. 1 In some instances, patients may require hemodialysis if symptoms persist, 6 but complete recovery to baseline function is expected within a week. 1, 12 Traditionally, peritoneal dialysis is not considered an efficient means for acyclovir clearance; 10 however, case reports of successful management of acyclovir and valacyclovir neurotoxicity via intensification of peritoneal dialysis exist, specifically with increased volume of hypertonic exchanges, without the need to convert to hemodialysis. 2, 6 Conclusion This case highlights a rare complication of a commonly prescribed antiviral agent. The onset of neurologic symptoms soon after medication initiation in a patient with end-stage renal disease, lack of fever and headache, and rapid resolution of symptoms after intensification of peritoneal dialysis are in keeping with valacyclovir neurotoxicity. Cerebrospinal fluid and MRI findings with acyclovir and valacyclovir neurotoxicity can be variable and may not reliably allow distinction from viral encephalitis. We aim to make clinicians aware that toxicity related to these antiviral agents may mimic infectious presentations clinically, biochemically and radiographically, and that risk is increased in those with impaired renal function.

Distinguishing acyclovir neurotoxicity from encephalomyelitis

Intensification of peritoneal dialysis improves valacyclovir neurotoxicity

Possible valacyclovir-related neurotoxicity and aseptic meningitis

Posterior reversible encephalopathy syndrome in end-stage kidney disease: not strictly posterior or reversible

Diagnosis and management of acute encephalitis: a practical approach

Acyclovir neurotoxicity in a peritoneal dialysis patient: report of a case and review of the pharmacokinetics of acyclovir

Molecular methods for diagnosis of viral encephalitis

A method for estimating the probability of adverse drug reactions

Case files of the Harvard medical toxicology fellowship: valacyclovir neurotoxicity and unintentional overdose

Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis

A case of acyclovir neurotoxicity presenting with atypical cerebrospinal fluid findings

Acyclovir neurotoxicity: clinical experience and review of the literature

Reversible brain MRI changes in acyclovir neurotoxicity

The authors thank Dr. Michael O'Keeffe from the Department of Medical Imaging at Sunnybrook Health Sciences Centre for his expertise in reviewing the MRI brain images.

Competing interests: Nisha Andany reports receiving research funds from Gilead Sciences, GlaxoSmithKline and Janssen as a site investigator for HIV clinical trials (research funds all paid to institution), outside of the submitted work. No other competing interests were declared. This article has been peer reviewed.The authors have obtained patient consent.Affiliations: Department of Medicine (Halani, Andany, Izenberg, Auguste), University of Toronto; Divisions of Infectious Diseases (Andany), and Neurology (Izenberg), and Nephrology (Auguste), Sunnybrook Health Sciences Centre, Toronto, Ont.

All of the authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

This is an Open Access article distributed in accord ance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ Correspondence to: Bourne Auguste, Bourne.Auguste@sunnybrook.ca CMAJ invites submissions to "What is your call?" Clinical details (including images) are presented with a multiple-choice question about the diagnosis. The answer and a brief discussion of the condition follow. We specifically invite submissions illustrating common or important radiographic and electrocardiographic diagnoses of appeal to a general audience. We require authors to obtain consent from the patient for publication of his or her story. Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj